Matt Jones’ Post

Geographic atrophy treatment news from Market Scope: Inflammasome Therapeutics reported on Jan. 15 positive topline three-month data from a Phase I/II trial of its K8 dual inflammasome inhibiting implant in geographic atrophy (GA). The mean lesion growth in K8-treated eyes was 66 percent less than that of untreated eyes at three months after a single implant injection, as measured by fundus autofluorescence (FAF) imaging. #clinicaltrial #geographicatrophy #GAtreatment #dryAMD #inflammation

It’s been a really positive experience to be a part of the 2024 MedTech Innovator Accelerator Cohort, especially as we prepare to submit our PMA application to the FDA. The Neuspera Sacral Neuromodulation System is a minimally invasive, ultra-miniaturized system designed to treat OAB, while eliminating the need for an implanted battery. It is a true innovation in a field that has seen only incremental improvements over the past decade and led to our recognition by Medtech Innovator. For more about the exciting recent milestones at Neuspera, check out our news page, here: https://lnkd.in/gSEp8WQJ. Note: The Neuspera Sacral Neuromodulation System is limited to investigational use only. #Neuspera #OAB #urology #neuromodulation #medtech #medicaldevice #tech #digitalhealth #mti #cohort #strategics 

✨ Excited to share a new technique at the upcoming VeithSymposium in New York (November 18-22) ✨ I’m honored to have been accepted as Associate Faculty to present my innovative surgical technique: “Misalignment In FEVAR: Technique To Ensure Cannulation Of Target Arteries In PMEG: In Vitro Testing And Proposal For An Off-The-Shelf Device.” This technique, which I developed and am working to refine, is designed to optimize target artery cannulation in PMEG procedures. Initial in vitro testing has shown promising results, and my goal is for this approach not only to enhance FEVAR procedures but to inspire the creation of a readily available device that can support surgeons in the field. I hope this innovation will spark interest within the vascular community, and perhaps even attract potential collaborators for the journey toward final design. To my colleagues and vascular health professionals, I look forward to connecting and exchanging ideas at VeithSymposium! #VeithSymposium #PMEG #VascularSurgery #FEVAR #MedicalInnovation #SurgicalInnovation #Endovascular #MedTech #HealthcareInnovation #MedicalDevice #InVitroTesting #VascularCommunity

Evergen (Formerly RTI Surgical) said this move signals a strategic evolution into a premier CDMO providing biosolutions in regenerative medicine.

A new study published today in the Journal of Vascular and Interventional Radiology shows that a minimally invasive treatment for osteoarthritis (OA) in the knees may have a lasting benefit of at least 2 years. The study of genicular artery embolization (GAE) followed 40 patients with moderate-to-severe symptomatic knee OA after their GAE treatment and measured pain scores throughout the 24-month study period. 25 of the patients (66%) reported improvement at 1 year. Of those 25, 18 patients (72%) have since reported continued relief of symptoms at 2 years. Overall, 18 of the original 38 patients (47%) who remained in the study throughout the 2-year follow up period reported a greater than 50% reduction in OA symptoms over the 2 years. “For patients who are not candidates for knee replacement surgery, our study shows that GAE provides durable benefit to many patients, measurable for up to 2 years, a great leap forward in offering this cohort lasting relief,” said Siddharth A Padia, MD, FSIR, the lead author of the study and professor of radiology at UCLA Health. #PainAwarenessMonth Read more: https://brnw.ch/21wN3if

⚡ ZAP Surgical Systems, Inc. secured $78m in a financing round led by and in partnership with Chinese healthcare company Qingdao Baheal Medical. The funding will further the manufacturing and distribution efforts of ZAP Surgical’s ZAP-X Gyroscopic Radiosurgery platform for non-invasive stereotactic radiosurgery procedures to treat brain tumours, lesions, and other conditions of the head and neck. 🚀 ZAP Surgical founder and CEO John Adler commented: “We founded ZAP Surgical to address a clear need: enabling more patients to access state-of-the-art radiosurgery without the prohibitive costs and infrastructure requirements that limit so many providers." 🔗 Read more: https://lnkd.in/dycy4iYY #MedicalDevice #MedTech #MedicalEquipment #HealthTech #SeriesA #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

Bioretec Updates Financial Targets Today, 4 October 2024, Bioretec Ltd announced a revision of its financial targets following the acceleration of product development for the RemeOs™ Spinal Interbody Cage. This shift comes after the Breakthrough Device Designation granted by the US FDA in March 2024, emphasising Bioretec's commitment to bringing innovative solutions to market. Updated Financial Targets: ·      Net sales: EUR 65 million by the end of 2028 and over EUR 100 million by 2030 (previous target: EUR 62 million by the end of 2027). ·      Positive cash flow from operating activities: This is expected by the end of 2027 (previous target: by the end of 2026). The changes reflect both the delay in receiving market authorisation for the RemeOs™ Trauma Screw in Europe and the faster net sales growth expected from the accelerated development of the RemeOs™ Spinal Interbody Cage starting in 2028. Exciting times ahead as Bioretec push forward with groundbreaking innovation! https://lnkd.in/d8FVtvE3 #Bioretec #FinancialUpdate #GrowthStrategy #MedicalDevices #SpinalSurgery #HealthcareInnovation #RemeOsCage #TraumaScrew #BusinessTransformation

News: Avation Medical announces Jason Whiting has been named as Chief Executive Officer, bringing 25 years of success in the MedTech industry. Please join us in welcoming Jason to the Avation team! 📅 For more details, read the full press release on our website: Avation.com #Vivally #innovation #neuromodulation #OAB #AvationMedical #NewCEO Jason Whiting

#Pterygium is a benign fibrovascular growth that extends from the conjunctiva to the corneal surface that can cause eye irritation, redness and impair vision. It most often affects people exposed to high levels of ultraviolet light or certain other environmental factors during outdoor work or leisure activities.      While there are no FDA-approved drugs for pterygium, Cloudbreak is developing the first potential therapy for this condition, which is now in Phase 3 clinical trials. Learn more about our work:  https://lnkd.in/e_UnxjTr

👍 InnovHeart announced the first trans-septal clinical trial implant of its proprietary Saturn transcatheter mitral valve, which led to excellent hemodynamic results for the patient. The procedure was part of system’s ongoing European clinical trial, the CASSINI-EU study. 👏Best of luck in the trial to the medical team, CEO David Wilson, and CTO Giovanni Righini! 🔗 Learn more: https://lnkd.in/e4RXksht 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/echiXdGC #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions